Executive interview – Actinogen Medical

Published on 22 November 2019

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases.

In this video, the company’s chief executive officer Bill Ketelbey provides an update on recent developments, R&D progress and expected newsflow.

Share this with friends and colleagues